Objective To observe the expression of TLR4 in hepatocellular carcinoma cell line HepG2 after transient and stable HBV genome transfection. Methods Immunofluorescence flow cytometry was used to detect mean fluorescence intensity (MFI) of TLR4 and TLR4 positive cell percentage in hepetocellular carcinoma cell lines HepG2 and HepG2. 2.15. Various doses of HBV DNA plasmid were transfected into HepG2 cells with lipefectamine 2000. Immunofluoroscenee flow cytometry was used to detect MFI of TLR4 and TLR4 positive ceil rate of infected HepG2 ceils. Trypan blue staining was used to examine the sum of living cells. Results MFI of TLR4 and TLR4 positive cell rate of HepG2.2.15 cells were significantly higher than those in HepG2 cells (both P' <0. Ol). MFI of TLR4 and TLR4 positive cell rate of HepG2 cells transfected by various doses of HBV DNA were significantly higher than those in control group (all P' < 0. 01). MFI of TLR4 and TLR4 positive cell rate of infected HepG2 cells were positively correlated with the doses of HBV DNA (both P' <0. 01) and negatively correlated with the sum of living cells (both P' <0. 01). Conclusions Enhanced expression of TLR4 appeared in HepG2 cells with both transient and stable HBV infection, along with reduction of living cells.

OBJECTIVE:To systematically evaluate the clinical efficacy and safety of Compound Huangbo liquid combined with chemical medicine in the treatment of ulcerative colitis (UC),and to provide evidence-based reference.METHODS:Re trieved from CBM,Wanfang Database,VIP,CJFD,PubMed,EMBase and Cochrane Library,randomized controlled trials(RCTs) about Compound Huangbo liquid combined with chemical medicine (trial group) vs.chemical medicine alone (control group) in the treatment of UC were collected.Meta-analysis was performed by using Rev Man 5.3 statistical sofetware after literature scanning,data extraction and quality evaluation according to Cochrane reviewer's handbook 5.1.0.RESULTS:A total of 8 RCTs were included,involving 737 patients.The results of Meta-analysis showed that,response rate of trial group was significantly higher than that of control group,with statistical significance [OR=4.69,95 ％ CI(3.00,7.34),P＜0.001];there was no statistical significance in the incidence of ADR between 2 groups [OR=0.94,95 ％ CI (0.48,1.84),P=0.86].CONCLUSIONS:Compound Huangbo liquid combined with chemical medicine is better than chemical medicine alone for UC,and both have similar safety.

OBJECTIVE: To systematically evaluate therapeutic efficacy and safety of Compound kushen colon-release capsule versus related chemical drugs in treatment of ulcerative colitis (UC).METHODS: Retrieved from PubMed, Embase, Cochrane library, China Journal Full-text Database (CJFD), VIP, CBM and Wanfang database, RCTs about therapeutic efficacy (response rate, TCM syndrome, therapeutic efficacy of mucosal lesion) and safety (the incidence of ADR) of Compound kushen enteric-release capsule versus related chemical drugs in the treatment of UC were collected. Meta-analysis was conducted by using Rev Man 5. 3 statistical software after data extraction and quality evaluation with Cochrane 5. 1. 0. RESULTS: A total of 9 RCTs were included, involving 649 patients. The results of Meta-analysis showed that response rate [OR=2. 16, 95％CI(1. 28, 3. 63), P=0. 004] and therapeutic efficacy of mucosal lesion [OR=2. 42, 95％ CI(1. 07, 5. 47), P=0. 03] of Compound kushen colon-release capsule were significantly higher than that of chemical drugs in the treatment of UC, with statistical significance. There was no statistical significance in therapeutic efficacy of TCM syndrome [OR=1. 70, 95％CI(0. 87, 3. 32), P=0. 12] or the incidence of ADR between 2 groups. CONCLUSIONS: Therapeutic efficacy of Compound kushen colon-release capsule is better than that of related chemical drugs in the treatment of UC with similar safety.

Androgen insensitivity syndrome (AIS) is a recessive single gene disease of X chromosome, which is rare clinically and has a very low incidence in newborn boys. This is mainly due to the abnormal pathway in which androgens play a role, resulting in sexual differentiation disorder in patients. A pair of identical twins were admitted to our hospital, and a new pathogenic mutation site of the androgen receptor gene was found, resulting in an androgen insensitivity phenotype.

Background: Subclinical hypothyroidism (SCH) is the most common thyroid dysfunction, and its relationship with blood pressure (BP) has been controversial. The aim of the study was to analyze the association between SCH and newly-diagnosed hypertension. Methods: Based on data from the Thyroid disease, Iodine nutrition and Diabetes Epidemiology (TIDE) study, 49,433 euthyroid individuals and 7,719 SCH patients aged ≥18 years were enrolled. Patients with a history of hypertension or thyroid disease were excluded. SCH was determined by manufacturer reference range. Overall hypertension and stage 1 and 2 hypertension were diagnosed according to the guidelines issued by the American College of Cardiology/American Heart Association in 2017. Results: The prevalence of overall hypertension (48.7%), including stage 1 (28.9%) and 2 (19.8%) hypertension, increased significantly in SCH patients compared with euthyroid subjects. With elevated serum thyroid stimulating hormone (TSH) level, the hypertension prevalence also increased significantly from the euthyroid to different SCH subgroups, which was more profound in females or subjects aged <65 years. The age- and sex-specific regression analysis further demonstrated the same trends in the general population and in the 1:1 propensity matched population. Similarly, several BP components (i.e., systolic, diastolic, and mean arterial BP) were positively associated with TSH elevation, and regression analysis also confirmed that all BP components were closely related with SCH in female subjects aged <65 years. Conclusion The prevalence of hypertension increases for patients with SCH. SCH tends to be associated with hypertension and BP components in females younger than 65 years.

Background: Subclinical hypothyroidism (SCH) is the most common thyroid dysfunction, and its relationship with blood pressure (BP) has been controversial. The aim of the study was to analyze the association between SCH and newly-diagnosed hypertension. Methods: Based on data from the Thyroid disease, Iodine nutrition and Diabetes Epidemiology (TIDE) study, 49,433 euthyroid individuals and 7,719 SCH patients aged ≥18 years were enrolled. Patients with a history of hypertension or thyroid disease were excluded. SCH was determined by manufacturer reference range. Overall hypertension and stage 1 and 2 hypertension were diagnosed according to the guidelines issued by the American College of Cardiology/American Heart Association in 2017. Results: The prevalence of overall hypertension (48.7%), including stage 1 (28.9%) and 2 (19.8%) hypertension, increased significantly in SCH patients compared with euthyroid subjects. With elevated serum thyroid stimulating hormone (TSH) level, the hypertension prevalence also increased significantly from the euthyroid to different SCH subgroups, which was more profound in females or subjects aged <65 years. The age- and sex-specific regression analysis further demonstrated the same trends in the general population and in the 1:1 propensity matched population. Similarly, several BP components (i.e., systolic, diastolic, and mean arterial BP) were positively associated with TSH elevation, and regression analysis also confirmed that all BP components were closely related with SCH in female subjects aged <65 years. Conclusion The prevalence of hypertension increases for patients with SCH. SCH tends to be associated with hypertension and BP components in females younger than 65 years.